A股異動丨腦機接口概念股活躍 高德紅外漲停 科大訊飛、力合科創漲超5%
A股腦機接口概念股表現活躍,其中,董事長稱多個腦機接口技術已超馬斯克,高德紅外強勢漲停,科大訊飛、力合科創漲超5%,浙大網新、偉思醫療、航天發展、復旦復華跟漲。消息上,高德紅外董事長黃立在亞布力論壇年會表示,公司5年前就開展了腦機接口研究,並在不斷突破腦機接口頂尖技術。高德紅外實現了65000個通道的腦機接口,遠超馬斯克的3072個通道,是馬斯克的20倍,並且實現了雙向信息的讀取與寫入,而馬斯克的技術則爲單向。他直言,“很多技術層面的指標,我們已超過埃隆·馬斯克的Neuralink公司。”據麥肯錫測算,全球腦機接口醫療應用的潛在市場規模在2030年至2040年有望達到400億美元至1450億美元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.